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Figure 1. Examples of Biologically active S-linked 1,3,5-triazines.
Table 1
Solvent screening for the synthesis of S-linked 1,3,5- triazine tethered pe
metics 5
Entry Solvent Yie
a THF 38
b Acetonitrile 65
c EtOH 40
d 1,4-Dioxane 89
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An efﬁcient one-pot synthesis of Na-protected S-linked 1,3,5-triazine tethered peptidomimetics is
described. The protocol involves a three-component condensation reaction employing Na-protected
amino alkyl isothiouronium salt, formaldehyde and amino acid ester or aryl amine as reactants. Various
aryl amines with substitutions and amino acids with simple as well as bifunctional side chains were
employed to obtain triazine tethered peptidomimetics in good yield.
 2014 Published by Elsevier Ltd.R
ptidomi-
ld (%)Peptidomimetics have aroused great interest due to their wide
utility in developing new therapeutic agents and in drug design.1
One of the useful approaches for the synthesis of such peptidomi-
metics involves the incorporation of heterocyclic units at one or
more peptide bonds. In this context, triazoles, tetrazoles, thiazoles,
oxazoles, oxadiazoles and many other biologically important
heterocycles have been incorporated into the peptide backbone
and their biological properties have been studied.2
1,3,5-Triazine is an important heterocyclic unit that has found
useful applications as antimicrobial and antitumor agents.3 It
was also used as supramolecular agent,4 and in the synthesis of
dyes,5 as well as DNA cleavage reagent.6 Triazine derivatives also
showed non-peptidic prokineticin antagonist7 and analgesic prop-
erties.8 The S-linked 1,3,5-triazine derivatives also exhibit a wide
range of pharmacological properties. Brown and co-workers9
described the synthesis of MAC13243, 1 a new antibacterial com-
pound which inhibits the activity of LolA protein, a crucial compo-
nent of the lipoprotein targeting pathway in bacteria (Fig. 1).
Belonging to the similar class, 5-chlorouracil-linked pyrazolo
1,3,5-triazines, 2 serve as thymidine phosphorylase inhibitor.10
In an earlier report, Ralbovsky et al.,11 described the synthesis of
triazinedione through two different methods. In the ﬁrst method,
commercially available sulfonic acid salt of 2-methyl isothiourea
was treated with isocyanate in the presence of NaOH to form anintermediate which was then cyclized using methyl chloroformate
and Et3N at 10 C to rt to obtain the triazinediones. Parallelly,
commercially available thiourea was treated with CH3Cl in the
presence of MeOH to prepare isothiourea as an intermediate which
was then cyclized with N-chlorocarbonylisocyanate to yield
triazinedione. Kong et al.,12 reported the synthesis of S-linked
1,3,5-triazine-2,4-diones through cyclization of the intermediate
obtained by the reaction of ethoxycarbonylisothiocyanate, methyl
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Scheme 1. Synthesis of S-linked 1,3,5-triazine tethered peptidomimetics 5.
Table 2
List of S-linked 1,3,5-triazine tethered peptidomimetics 5
Entry Reactant 4 Products 5 Yielda
(%)
a
FmocHN
S NH2
NH2+ I-
FmocHN
S
HN N
N 89
b
FmocHN
S NH2
NH2+ I-
FmocHN
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HN N
N
Cl
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a Yields correspond to the isolated pure S-linked 1,3,5-triazine-tethered
peptidomimetics.
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by treatment with isocyanate at 60 C. Lam and co-workers13
described the preparation of S-linked triazines using Mukaiyama
reagent in the presence of DMAP at about 60–110 C. These meth-
ods inherit certain limitations wherein the isocyanates employed
for the reaction are not commercially available and are moisture
sensitive and toxic, which otherwise poses difﬁculty whileN N
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Scheme 2. Plausible pathways for the formation of Na-protehandling. Also the methods described involve long reaction
duration and harsh reaction conditions. Zhao et al.14 reported the
synthesis of Na-Cbz-amino acyl derived 3,5,6-trisubstituted
1,2,4-triazines using Cbz-protected amino acyl hydrazides and
1,2-diones in the presence of excess NH4OAc at 180 C.
Our group reported several new classes of peptidomimetics
possessing heterocycles such as 1,3,4,-oxadiazole,15 1,2,4,-oxadiaz-
ole,16 1,3,4,-thiadiazole,17 triazoles18 and tetrazoles.19 This list also
includes Fmoc-protected amino alkyl S/Se-linked tetrazoles20 and
Z/Boc-protected S-linked oxadiazole tethered peptidomimetics.21
Thus, with the continuing interest in designing heterocycle teth-
ered peptidomimetics we envisaged the synthesis of the S-linked
1,3,5-triazine moiety incorporated into the peptide backbone.
The starting material, Na-protected amino alkyl isothiouronium
salt 4 required for the present studywas prepared through the liter-
ature protocol as reported earlier by our group.22 The Na-protected
amino acid was subjected to reduction and then to Mitsunobu con-
ditions to form iodo compound. Thus obtained iodo compound was
then treated with thiourea in acetone under argon atmosphere at
reﬂux temperature for about 8–10 h to obtain corresponding iso-
thiouronium salt, which was used as such for the next step.
In an initial study, isothiouronium salt derived from Fmoc-Phe-
OH, that is, Fmoc-Phe-w[CH2-SC(NH)NH2.HI] 4a was made to react
with formaldehyde (37 wt % solution in water) and benzylamine as
a test case in the presence of TEA in THF at rt. The product 5a was
obtained albeit in very low yield. The four solvents viz acetonitrile,
EtOH, 1,4-dioxane and MeOH (Table 1) were screened in parallel
reactions. An impressive yield of 89% of 5a was isolated when
the reaction was carried out using 1,4-dioxane as solvent, in the
presence of 1.5 equiv of TEA, 2.0 equiv of HCHO, 1.5 equiv of amine
and 1.0 equiv of isothiouronium salt (Scheme 1).
With the optimized reaction conditions in hand, the generality
of the present protocol was tested by using aryl amines which
afforded the title molecules in good yield (Table 2). A plausible
reaction mechanism was proposed for the formation of compound
5 (Scheme 2).S
R
HN N
N
R1
5
+
R1N
H
HN
NH
S NHPg
R
H H
O
H2O
_
..
(I)
(II)
H2N
R1H H
O
N R
1
H
H
PgHN
R
S N
NH
H
H..
cted S-linked 1,3,5-triazine tethered peptidomimetics 5.
PgHN
R
S NH2
H2N COOMe
R1
i) TEA, HCHO 37%
1,4-dioxane
PgHN
R
S
HN N
N
COOMe
R1
74
ii)NH
+
I
_
PG = Fmoc, Cbz or Boc group
"One-pot"
6
R, R1 = amino acid side chain
Scheme 3. Synthesis of Na-protected S-linked 1,3,5-triazine tethered dipeptidom-
imetics 7.
Table 3
List of Na-protected S-linked 1,3,5-triazine tethered dipeptidomimetics 7
Entry Reactant 4
a
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M. Krishnamurthy et al. / Tetrahedron Letters 55 (2014) 5609–5612 5611In the ﬁrst step of the reaction, the amine was condensed with
formaldehyde producing an imine intermediate [I], which subse-
quently reacts with a molecule of N-protected amino alkyl isot-
hiourea, giving an intermediate [II]. This intermediate [II] in the
presence of formaldehyde undergoes dehydrocyclization to form
Na-protected S-linked 1,3,5-triazine tethered peptidomimetics.
The formation of the desired product can also be explained through
another possible pathway wherein deprotonated isothiouronium
salt reacts with HCHO to give the corresponding imine-like diun-
saturated intermediate. This will then react with the intermediateProducts 7 Yield (%)
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5612 M. Krishnamurthy et al. / Tetrahedron Letters 55 (2014) 5609–5612(I) in an aza-Diels Alder like process to afford the product 5 as illus-
trated in Scheme 2.
In the next part of the study, we focused our attention towards
the synthesis of dipeptidomimetics containing S-linked 1,3,5-tria-
zines. In a typical experiment, Fmoc-Phe-w[CH2-SC(NH)NH2HI]
4d in 1,4-dioxane was treated with HCHO (37% wt, in solution of
water), TEA and followed by the addition of a solution of H-Leu-
OMe (deprotonation of HCl.H-Leu-OMe was carried out using zinc
dust) in 1,4-dioxane. The reaction mixture was initially heated
until the turbid solution turns into a clear solution. Then it is
stirred at rt for about 6 h and the completion of the reaction was
monitored through TLC. A simple work-up resulted in the corre-
sponding product 7d. The crude product was then puriﬁed through
column chromatography using CHCl3 and MeOH as eluent (95:5) to
afford the pure product in 85% yield (Scheme 3). The efﬁcacy of this
protocol was demonstrated by the synthesis of a series of com-
pounds employing several Na-protected amino alkyl isothiouroni-
um salts and amino acid methyl esters in moderate to good yields
(Table 3).23 All the compounds were isolated as stable ones and
characterized through mass, 1H and 13C NMR analyses.24
The possibility of racemization, if any, during the synthesis of S-
linked 1,3,5-triazine tethered peptidomimetics via the present pro-
tocol was assessed through RP-HPLC analysis of the intentionally
made diastereomers, that is, Fmoc-L-Phg-triazine-(R)-PEA 5f and
Fmoc-L-Phg-triazine-(S)-PEA 5g.25 From these results it was found
that the protocol was racemization-free and yielded optically pure
products.
In the present Letter, we have demonstrated an application of
Na-protected amino alkyl isothiouronium salts as precursor units
for the preparation of S-linked 1,3,5-triazine tethered peptidomi-
metics in one pot. The synthetic protocol implemented was
straightforward, mild and avoids the usage of isothiocyanates used
in earlier reports, which were albeit toxic and hazardous and han-
dling of such molecules is difﬁcult. The products were obtained in
good yields and characterized by mass, 1H and 13C analyses.
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Gradient 0.1% TFA, acetonitrile 30–100% in 30 min with a ﬂow rate of 0.5 ml/
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